FDA advisory panel narrowly withholds support for AstraZeneca’s combo in breast cancer

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor

AKUMS launches Aztreonam-Avibactam injection to combat multidrug-resistant infections

The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand

Azelis posts resilient Q1 as acquisitions mask organic slowdown and cash flow strengthens

Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance

FDA presses 2,200+ companies to fix missing clinical trial results

Move amid evidence of widespread reporting gaps

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Agilent bags FDA nod for key cancer diagnostic

The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

Wockhardt’s breakthrough antibiotic Zaynich wins key regulatory nod in India

Roche reports Phase III persevERA breast cancer trial results

Giredestrant shows promise despite missing primary goal